Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory or relapsed acute lymphoblastic leukemia~  * Must be in first relapse or have failed to achieve complete remission with 1 prior regimen~* Prior central nervous system (CNS) leukemia allowed provided cerebrospinal fluid is normal~* ECOG Performance status of 0-3~* Bilirubin normal~* Creatinine normal~* Human immunodeficiency virus (HIV) negative~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Hepatitis B positivity~* Bacterial or fungal infection~* Infection requiring treatment with antibiotics~* Active cytomegalovirus infection by molecular detection methods~* Known hypersensitivity to alemtuzumab or its components~* Pregnant or nursing~* Other malignancy within the past 5 years except adequately treated basal cell skin cancer or cervical carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy, enzyme inhibitor therapy) (Type: EXPERIMENTAL): INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).